Also known as: Mounjaro
Tirzepatide is a novel peptide classified as a dual GIP (Gastric Inhibitory Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist. This innovative compound is primarily categorized under fat loss and metabolic peptides, designed to aid in the regulation of glucose metabolism and appetite control. Developed for therapeutic applications, Tirzepatide has garnered attention for its potential benefits in managing metabolic disorders.
Tirzepatide functions by activating both GIP and GLP-1 receptors, which play crucial roles in insulin secretion and appetite regulation.
When Tirzepatide binds to these receptors, it enhances insulin sensitivity and promotes satiety, leading to reduced food intake. This dual action not only helps in lowering blood sugar levels but also supports weight loss by modulating metabolic pathways.
Tirzepatide represents a promising advancement in the field of metabolic peptides, particularly for its dual action on GIP and GLP-1 receptors. Its potential applications in weight management and glycemic control underscore its relevance in addressing obesity and related metabolic disorders.
Last updated: Jan 8, 2026
Tirzepatide: What Dual Agonism Actually Does (2026 Research Guide)
Semaglutide: What the Clinical Data Actually Shows (2026 Research Guide)